On Tuesday, MEI Pharma Inc (NASDAQ:MEIP)’s shares declined -6.28% to $2.24.
MEI Pharma Inc (MEIP) declared top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with formerly untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). The double-blind, placebo-controlled study enrolled a total of 102 patients, randomized one-to-one, at 19 sites in the U.S.
MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia.
Cytori Therapeutics Inc (NASDAQ:CYTX)‘s shares dropped -6.25% to $1.05.
Cytori Therapeutics Inc (CYTX) declared that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union (EU).
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy compriseing of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
At the end of Tuesday’s trade, Super Micro Computer, Inc. (NASDAQ:SMCI)‘s shares dipped -6.07% to $34.81.
Super Micro Computer, Inc. (SMCI) declared third quarter of fiscal 2015 financial results for the quarter ended March 31, 2015.
Fiscal 3rd Quarter Highlights
- Quarterly net sales of $471.2 million, down 6.3% from the second quarter of fiscal year 2015 and up 26.1% from the same quarter of last year.
- GAAP net income of $23.1 million, down 26.2% from the second quarter of fiscal year 2015 and up 39.1% from the same quarter of last year.
- GAAP gross margin of 16.3%, down from 16.8% in the second quarter of fiscal year 2015 and up from 15.3% in the same quarter of last year.
Super Micro Computer, Inc., together with its auxiliaries, develops and provides high performance server solutions based on modular and open-standard architecture. The company offers a range of server, storage, blade, workstation, and full rack solutions, in addition to networking devices, server administration software, and technology support and services.
Alpha Natural Resources, Inc. (NYSE:ANR), ended its Tuesday’s trading session with -5.92% loss, and closed at $0.851.
Alpha Natural Resources, Inc. (ANR) declared that the Company has been notified by the New York Stock Exchange (the “NYSE”) that its common stock does not presently satisfy one of the NYSE’s standards for continued listing and trading on the exchange. The NYSE requires that the average closing price of a listed company’s common stock be at least $1.00 per share over any period of 30 successive trading days. As of April 13, 2015, the average closing price per share of the Company’s common stock over the preceding 30 trading-day period was $0.99.
Alpha Natural Resources, Inc., together with its auxiliaries, engages in extracting, processing, and marketing steam and metallurgical coal in Kentucky, Pennsylvania, Virginia, West Virginia, and Wyoming. It operates through two segments, Eastern Coal Operations and Western Coal Operations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
